Stocks discussed in the in-depth session of Jim Cramer’s Mad Money TV program, Friday June 20.
Gardner Denver (NYSE:GDI)
Cramer recommended Gardner Denver, a manufacturer of components to produce and ship oil as yet another way to make money on the ever-rising commodity. Oil's jump on Friday did not affect the stock, and Cramer sees this value gap as a golden opportunity. "Gardner doesn't just make things, it makes things smaller, better and more energy efficient," said Cramer. The company is rated first or second in all of its businesses, and has estimates and a multiple which, according to Cramer are too low. Gardner Denver is trading at 13 times a $4 forward estimate, which is 50 cents lower than it should be and lower than its competitors. Cramer expects GDI to reach the same level as its peers in the mid-60s by the end of the year, which would mean a 20% bounce.
Speculation Friday: Oil Sands Quest (BQI)
Would anyone buy an oil company without revenues on one or two catalysts which might or might not pan out? While this kind of speculation isn't for the faint-hearted, Cramer sees the sense in buying Oil Sands Quest, which owns 500,000 acres in the Saskatchewan oil sands. Oil sands produce "dirty oil" which is harder to refine. Although the company has no revenues yet, its real estate holdings alone could give it an offer which may bring up the stock 156%. Even a more modest offer may move the stock price from $6.24 to $8.34. Cramer emphasized once again that this $6 stock is high-risk, so he would do research, buy incrementally and use limit orders.
Game Plan: CVS Caremark (NYSE:CVS), Walgreen (WAG), Rite-Aid (NYSE:RAD), Darden (NYSE:DRI), Nike (NYSE:NKE), Research in Motion (RIMM), ConAgra (NYSE:CAG), Discover Financial (NYSE:DFS), Lennar (NYSE:LEN), Micron (NASDAQ:MU), Accenture (NYSE:ACN)
Cramer expects the summer season on Wall Street to get off to a slow start unless oil makes a dramatic move. He doesn't think Walgreen will give a good report, but would buy CVS Caremark because Rite-Aid's report later in the week will be even worse, and Cramer believes CVS and Walgreen could become a duopoly in the pharmacy space. Cramer doesn't think Darden will do as badly as many expect, and if there is a decline, he would buy before it reports on Tuesday. Looking to the Olympics, Cramer would buy Nike on weakness if it falls following its report on Wednesday. If it doesn't drop, he'd give it a miss. Cramer thinks Accenture on Thursday will be “ terrific in a day otherwise shrouded in gloom," as he expects bad news from ConAgra, Rite-Aid, Discover Financial, Micron and Lennar.
CEO Interview: Jonah Shacknai, Medicis Pharmaceutical (MRX)
Shacknai discussed Medicis' new acquisition of LipoSonix Technology, which breaks up fat under the skin using ultrasound technology. This procedure saves consumers the trouble and scars of liposuction, and Shacknai claims patients can lose a few inches. However, analysts are not thrilled with the acquisition and doubt the technology will make it past the FDA. Shacknai blames the negative environment and says LipoSonix is doing well in Europe. Cramer was neutral on Medicis, but said the criticism was "small-minded" and recommended doing one's own research.
Seeking Alpha publishes a summary of Jim Cramer's stock picks every day including: Mad Money Recap, Lightning Round, Stop Trading and his Wall Street Confidential Picks.
Get Cramer's Picks by e-mail -- it's free and takes only a few seconds to sign up.
Seeking Alpha is not affiliated with Jim Cramer, CNBC or TheStreet.com